---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-26-000013"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T22:57:38.718936+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma reports record Q4 revenue $247M, EPS $1.18; reaffirms 2026 guidance

## Summary
- Q4 total net revenue $247.1M (+29.6% YoY); Rare Disease segment $131.3M (+50.8%), Cortrophin Gel $111.4M (+87.6%).
- Q4 GAAP diluted EPS $1.18; adjusted diluted EPS $2.33. Full year revenue $883.4M (+43.8%).
- Generics Q4 revenue $100.8M (+28.2%) driven by partnered launch and new products.
- Reaffirms FY2026 guidance: total revenue $1.055-1.115B; Cortrophin Gel $540-575M; adjusted EBITDA $275-290M.
- Cash and equivalents $285.6M; operating cash flow $185.2M in 2025.

## SEC filing metadata
- accession: 0001023024-26-000013
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/0001023024-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/ani-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-26-000013
- JSON: https://secwatch.observer/filing/0001023024-26-000013.json
- Plain text: https://secwatch.observer/filing/0001023024-26-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.